These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 25348062)

  • 21. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance.
    Zitvogel L; Galluzzi L; Smyth MJ; Kroemer G
    Immunity; 2013 Jul; 39(1):74-88. PubMed ID: 23890065
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-transforming growth factor beta receptor II antibody has therapeutic efficacy against primary tumor growth and metastasis through multieffects on cancer, stroma, and immune cells.
    Zhong Z; Carroll KD; Policarpio D; Osborn C; Gregory M; Bassi R; Jimenez X; Prewett M; Liebisch G; Persaud K; Burtrum D; Wang S; Surguladze D; Ng S; Griffith H; Balderes P; Doody J; Schwartz JD; Youssoufian H; Rowinsky EK; Ludwig DL; Witte L; Zhu Z; Wu Y
    Clin Cancer Res; 2010 Feb; 16(4):1191-205. PubMed ID: 20145179
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Angiogenesis inhibition and tumor-immune interactions with chemotherapy by a control set-valued method.
    Kassara K; Moustafid A
    Math Biosci; 2011 Jun; 231(2):135-43. PubMed ID: 21377480
    [TBL] [Abstract][Full Text] [Related]  

  • 24. How regulatory CD25(+)CD4(+) T cells impinge on tumor immunobiology? On the existence of two alternative dynamical classes of tumors.
    Leon K; Garcia K; Carneiro J; Lage A
    J Theor Biol; 2007 Jul; 247(1):122-37. PubMed ID: 17412365
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of chemokines and chemokine receptors in shaping the effector phase of the antitumor immune response.
    Franciszkiewicz K; Boissonnas A; Boutet M; Combadière C; Mami-Chouaib F
    Cancer Res; 2012 Dec; 72(24):6325-32. PubMed ID: 23222302
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Capitalizing on the immunogenicity of dying tumor cells.
    Fonseca C; Dranoff G
    Clin Cancer Res; 2008 Mar; 14(6):1603-8. PubMed ID: 18347160
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mathematical Based Calculation of Drug Penetration Depth in Solid Tumors.
    Namazi H; Kulish VV; Wong A; Nazeri S
    Biomed Res Int; 2016; 2016():8437247. PubMed ID: 27376087
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Antitumoral action of interferons and interleukins in combination with radiotherapy. Part I: immunologic basis].
    Herskind C; Fleckenstein K; Lohr J; Li CY; Wenz F; Lohr F
    Strahlenther Onkol; 2004 Apr; 180(4):187-93. PubMed ID: 15057428
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mathematical and numerical analysis for a model of growing metastatic tumors.
    Barbolosi D; Benabdallah A; Hubert F; Verga F
    Math Biosci; 2009 Mar; 218(1):1-14. PubMed ID: 19121638
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Effect of chemotherapy on anticancer immune effector cells].
    Saijo N
    Gan To Kagaku Ryoho; 1983 Mar; 10(3):699-707. PubMed ID: 6410999
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Heterogeneity of the interaction of anticancer agents with the immune system and its possible relevance in chemoimmunotherapy.
    Spreafico F
    Oncology; 1980; 37 Suppl 1():9-18. PubMed ID: 7005792
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Control by Viability in a Chemotherapy Cancer Model.
    Serhani M; Essaadi H; Kassara K; Boutoulout A
    Acta Biotheor; 2019 Sep; 67(3):177-200. PubMed ID: 30949871
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapy burden, drug resistance, and optimal treatment regimen for cancer chemotherapy.
    Boldrini JL; Costa MI
    IMA J Math Appl Med Biol; 2000 Mar; 17(1):33-51. PubMed ID: 10757031
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mixed immunotherapy and chemotherapy of tumors: modeling, applications and biological interpretations.
    de Pillis LG; Gu W; Radunskaya AE
    J Theor Biol; 2006 Feb; 238(4):841-62. PubMed ID: 16153659
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immune cells as anti-cancer therapeutic targets and tools.
    Johansson M; Tan T; de Visser KE; Coussens LM
    J Cell Biochem; 2007 Jul; 101(4):918-26. PubMed ID: 17265430
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity.
    Smyth MJ; Dunn GP; Schreiber RD
    Adv Immunol; 2006; 90():1-50. PubMed ID: 16730260
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dynamic response of cancer under the influence of immunological activity and therapy.
    de Vladar HP; González JA
    J Theor Biol; 2004 Apr; 227(3):335-48. PubMed ID: 15019501
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A delay differential equation model for tumor growth.
    Villasana M; Radunskaya A
    J Math Biol; 2003 Sep; 47(3):270-94. PubMed ID: 12955460
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mathematical modeling of ovarian cancer treatments: sequencing of surgery and chemotherapy.
    Kohandel M; Sivaloganathan S; Oza A
    J Theor Biol; 2006 Sep; 242(1):62-8. PubMed ID: 16580022
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimal robust control of drug delivery in cancer chemotherapy: a comparison between three control approaches.
    Moradi H; Vossoughi G; Salarieh H
    Comput Methods Programs Biomed; 2013 Oct; 112(1):69-83. PubMed ID: 23891423
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.